Clinical Trials Browser

Phase 3 × Melanoma × Introns × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT03435302 2018-02-19

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Phase 3 Unknown

Melanoma

NCT00221702 2010-10-13

EADO

Phase 3 Completed

Melanoma, Neoplasm Metastasis, Drug-Related Side Effects and Adverse Reactions

NCT00226408 2006-06-21

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Phase 3 Unknown

Melanoma